AN2 Therapeutics (ANTX) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Organogenesis (ORGO) over the past year, gaining 270.2% versus a loss of 69.0%. AN2 Therapeutics is the larger company by market cap ($176.6 million vs $164.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | ORGO |
|---|---|---|
| Share price | $4.68 | $1.28 |
| Market cap | $176.61M | $164.70M |
| 1-day change | -3.51% | -3.03% |
| YTD return | +325.44% | -75.29% |
| 1-year return | +270.23% | -69.01% |
| 5-year return | — | -88.31% |
| EPS (TTM) | $-1.05 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $7.08 |
| 52-week low | $1.00 | $1.25 |
| Distance from 52-week high | -34.91% | -81.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.31% | +56.25% |
| Average volume | 235.07K | 772.95K |
| Shares outstanding | 37.74M | 128.67M |
| Employees | 21 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ORGO by 339.2 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
ANTX vs ORGO FAQ
Which is bigger, AN2 Therapeutics or Organogenesis?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $176.61M compared with $164.70M for Organogenesis (ORGO).
Which stock has performed better over the past year, ANTX or ORGO?
ANTX returned +270.23% over the past 12 months, compared with -69.01% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Organogenesis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.